The UK and US have forged a landmark trade agreement that will ensure no import taxes on British medicine shipments going into the American market.
Key Provisions of the Pact
In exchange for the tariff guarantee, the UK has agreed to increase expenditure on medicines through the public health system. This pledge ensures that import taxes on these vital products will stay at nothing for a period of three years.
This development follows previous statements to hike import taxes on branded drug imports, with potential rates mentioned reaching 100%.
"This arrangement with the UK reinforces the worldwide climate for cutting-edge drugs and establishes long-overdue balance to U.S.–U.K. medicine commerce," a statement said.
Trade Significance
Drugs constitute one of the the United Kingdom's most significant goods shipped to the America, which is clearly the biggest buyer for leading British pharmaceutical firms.
Statistics indicate that in the 12 months leading up to the third quarter, the UK sold pharmaceutical products totaling £11.1bn to the US. This figure made up nearly one-fifth of British export trade in that timeframe.
"This agreement secures jobs, increases capital expenditure and sets the stage for the UK to become a global hub for life sciences," a government official commented.
Key UK Commitments
The deal entails several key changes from the United Kingdom:
- Revised Affordability Limit: The UK will raise the price threshold at which it considers new treatments to be prohibitively costly by 25%.
- Boosted Medicine Funding: There is a target to increase total health service expenditure on treatments from 0.3 percent of the national economy to 0.6% over the following ten-year period.
- Refund Ceiling: The sum pharmaceutical firms must return to the NHS to prevent overspending will be restricted at 15%. In the past, refunds topped twenty percent.
Recent Tensions
The pact follows a protracted row between the drug companies and the ministers over spending levels and approval rates.
These tensions were heightened by claims that US patients were charged a premium for the same drugs than patients in the UK and Europe.
Over the last 18 months, several major manufacturing plans in the UK have been delayed or cancelled, while substantial funding commitments have been pledged toward US facilities.
The Science Minister publicly accepted that the NHS had to increase expenditure on drugs, noting that its spending on drugs had decreased as a share of its resources over the last ten years.
